Le Lézard
Classified in: Health
Subjects: CHI, LEG, HSP, WOM, AVO

March Of Dimes Praises Passage Of S. 3029, The PREEMIE Reauthorization Act Of 2018


WASHINGTON, Sept. 12, 2018 /PRNewswire/ -- March of Dimes hailed U.S. Senate passage today of S. 3029, the PREEMIE Reauthorization Act of 2018, a bill to renew key laws aimed at preventing and treating preterm birth and its complications.

March of Dimes Foundation Logo (PRNewsfoto/March of Dimes Foundation)

"Preterm birth continues to be an under-recognized and under-appreciated crisis in maternal and child health," stated March of Dimes President Stacey D. Stewart. "Today, one in every 10 U.S. babies is born too soon, placing them at risk for a range of health consequences. Passage of the PREEMIE Act reaffirms the Senate's commitment to ensuring that every pregnancy is healthy and every baby gets the best possible start in life."

The PREEMIE Reauthorization Act renews a range of federal programs that support research, education and prevention efforts related to preterm birth. It would renew the Secretary's Advisory Committee on Infant Mortality and update its charge to include issues like maternal mortality and maternal immunization. S. 3029 would also create a new federal interagency committee to coordinate the many federal programs that impact preterm birth prevention either directly or indirectly. More information on the legislation is available here.

The PREEMIE Act is supported by a wide range of organizations committed to maternal and child health along with March of Dimes, including the American College of Obstetricians and Gynecologists, the American Academy of Pediatrics, the Association of Maternal and Child Health Programs, and the Children's Hospitals Association. A full list of organizations supporting the bill may be found here.

"March of Dimes is grateful to Senators Lamar Alexander and Michael Bennet for being steadfast champions of maternal and child health for many years," Ms. Stewart added. "This important step forward would not have been possible without their tireless support."

S. 3029 now proceeds to the House of Representatives. A companion bill, H.R. 6085, is sponsored by Reps. Anna Eshoo (D-CA) and Leonard Lance (R-NJ) and has bipartisan support.

About March of Dimes    
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook or follow us on Instagram and Twitter.

 

SOURCE March of Dimes


These press releases may also interest you

at 08:20
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse's...

at 08:15
Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for...

at 08:10
bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced David Elzi, Ph.D., has been named Vice President of...

at 08:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the availability of Over the Counter ("OTC") Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application ("ANDA") approval from the...

at 08:10
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company. This strategic...

at 08:10
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company's Deltacel-01 Phase 1 clinical trial....



News published on and distributed by: